Cancers, Vol. 16, Pages 1228: Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
We described the real-world persistence rate, patterns of use, and clinical outcomes in 309 patients with CLL receiving single-agent ibrutinib in first line (1L, n = 118), 2L (n = 127) and ≥3L (n = 64) in the prospective, real-world, Italian EVIdeNCE study. After a median follow-up of 23.9 months, 29.8% of patients discontinued ibrutinib (1L: 24.6%, 2L: 29.9%, ≥3L: 39.1%), mainly owing to adverse events (AEs)/toxicity (14.2%). The most common AEs leading to discontinuation were infections (1L, ≥3L) and cardiac events (2L). The 2-year retention rate was 70.2% in the whole cohort (1L: 75.4%, ...
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Francesca Romana Mauro Potito Rosario Scalzulli Lydia Scarf ò Carla Minoia Roberta Murru Paolo Sportoletti Ferdinando Frigeri Francesco Albano Nicola Di Renzo Alessandro Sanna Luca Laurenti Massimo Massaia Ramona Cassin Marta Coscia Caterina Patti Elsa P Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1229: Preliminary Experience with Virtual Monoenergetic Imaging and Iodine Mapping in the Primary Staging of Endometrial Cancer
In conclusion, computation of VMIs at 40 keV and color-coded iodine maps aids the assessment of endometroid adenocarcinoma in primary staging. (Source: Cancers)
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Stephanie Tina Sauer Henner Huflage Sara Aniki Christner Theresa Sophie Patzer Matthias Kiesel Anne Quenzer Andreas Steven Kunz Thorsten Alexander Bley Jan-Peter Grunz Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1211: Correction: Casili et al. Therapeutic Potential of BAY-117082, a Selective NLRP3 Inflammasome Inhibitor, on Metastatic Evolution in Human Oral Squamous Cell Carcinoma (OSCC). Cancers 2023, 15, 2796
Paterniti Emanuela Esposito In the original publication [...] (Source: Cancers)
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Giovanna Casili Sarah Adriana Scuderi Marika Lanza Alessia Filippone Deborah Mannino Raffaella Giuffrida Cristina Colarossi Marzia Mare Anna Paola Capra Federica De Gaetano Marco Portelli Angela Militi Salvatore Cuzzocrea Irene Paterniti Emanuela Esposito Tags: Correction Source Type: research

Cancers, Vol. 16, Pages 1213: Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications
ndl Circulating tumor cells (CTCs) are cells released from the primary and metastatic tumor and intravasate into the blood or lymphatic vessels, where they are transported to distant sites and act as seeds that initiate cancer metastases or the development of further lesions. Recent advances in CTC research have shown their relevance as prognostic markers for early and metastatic disease detection, predictive biomarkers for relapse, and response to medical intervention or therapy. The rapidly evolving landscape of CTC biology has opened new avenues for understanding cancer progression, metastasis, and treatment respons...
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Philip Salu Katie M. Reindl Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1212: Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment
This study focuses on developing liquid immunogenic fiducial eluter (LIFE) Biomaterial with components that include biodegradable polymers, nanoparticles, and an immunoadjuvant. LIFE Biomaterial is designed to provide image guidance during radiotherapy similar to clinically used liquid fiducials while enhancing therapeutic efficacy for advanced cervical cancer. C57BL6 mice were used to grow subcutaneous tumors on bilateral flanks. The tumor on one flank was then treated using LIFE Biomaterial prepared with the immunoadjuvant anti-CD40, with/without radiotherapy at 6 Gy. Computed tomography (CT) and magnetic resonance (MR) ...
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Michele Moreau Lensa S. Keno Debarghya China Serena Mao Shahinur Acter Gnagna Sy Hamed Hooshangnejad Kwok Fan Chow Erno Sajo Jacques Walker Philmo Oh Eric Broyles Kai Ding Akila Viswanathan Wilfred Ngwa Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1214: Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review
Harish Patel The prevalence of metabolic-associated fatty liver disease (MAFLD) is increasing globally due to factors such as urbanization, obesity, poor nutrition, sedentary lifestyles, healthcare accessibility, diagnostic advancements, and genetic influences. Research on MAFLD and HCC risk factors, pathogenesis, and biomarkers has been conducted through a narrative review of relevant studies, with a focus on PubMed and Web of Science databases and exclusion criteria based on article availability and language. Steatosis marks the early stage of MASH advancement, commonly associated with factors of metabolic syndrom...
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Haider Ghazanfar Nismat Javed Abeer Qasim George Sarin Zacharia Ali Ghazanfar Abhilasha Jyala Elona Shehi Harish Patel Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1215: Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors
o Cocco Since their discovery in 2002, BRAF mutations have been identified as clear drivers of oncogenesis in several cancer types. Currently, their incidence rate is nearly 7% of all solid tumors with BRAF V600E constituting approximately 90% of these diagnoses. In melanoma, thyroid cancer, and histiocytic neoplasms, BRAF hotspot mutations are found at a rate of about 50%, while in lung and colorectal cancers they range from 3% to 10% of reported cases. Though present in other malignancies such as breast and ovarian cancers, they constitute a small portion of diagnoses (<1%). Given their frequency along wit...
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Paola Roa Nicole Virginia Bremer Valentina Foglizzo Emiliano Cocco Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1216: Reviewing the Landscape of Cancer Survivorship: Insights from Dr. Lidia Schapira & rsquo;s Programs and Beyond
Cancers, Vol. 16, Pages 1216: Reviewing the Landscape of Cancer Survivorship: Insights from Dr. Lidia Schapira’s Programs and Beyond Cancers doi: 10.3390/cancers16061216 Authors: Viviana Cortiana Rabab Hunaid Abbas Soumiya Nadar Diksha Mahendru Jade Gambill Gayathri Pramil Menon Chandler H. Park Yan Leyfman The constantly escalating population of cancer survivors worldwide has prompted a focused exploration of their unique needs and experiences within the context of healthcare medicine. This review initiates its analysis inspired by Dr. Lidia Schapira’s insightful keynote confe...
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Viviana Cortiana Rabab Hunaid Abbas Soumiya Nadar Diksha Mahendru Jade Gambill Gayathri Pramil Menon Chandler H. Park Yan Leyfman Tags: Review Source Type: research

Cancers, Vol. 16, Pages 1218: Contrast Clearance Analysis (CCA) to Assess Viable Tumour following Stereotactic Radiosurgery (SRS) to Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC)
Conclusions: Our single-centre experience shows CCA to be feasible and useful in patients with NSCLC in cases of diagnostic uncertainty in MRI. It has helped guide treatment in the majority of patients, with subsequent outcomes following the implementation of the treatment based on the results, suggesting correct classification. Recommendations from our experience of the implementation include the careful consideration of the thin rim of the rapid contrast clearance and the timing of the CCA prior to surgery for suspected brain metastasis progression. (Source: Cancers)
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Shybi Mohamedkhan Sumeet Hindocha James de Boisanger Thomas Millard Liam Welsh Philip Rich Andrew D. MacKinnon Nicholas Williams Bhupinder Sharma Nicola Rosenfelder Anna Minchom Tags: Communication Source Type: research

Cancers, Vol. 16, Pages 1219: In-Hospital Mortality and Associated Factors among Colorectal Cancer Patients in Germany
Conclusions: Our findings underscore the critical role of renal failure, peritonitis, acute posthemorrhagic anemia, and respiratory failure in influencing the mortality outcomes of colorectal cancer patients during hospitalization. The awareness and management of these risk factors may guide clinicians in formulating targeted interventions to improve patient outcomes and enhance the quality of care for individuals with colorectal cancer. (Source: Cancers)
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Karel Kostev Sarah Krieg Andreas Krieg Tom Luedde Sven H. Loosen Christoph Roderburg Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1217: Longitudinal Assessment of Quality of Life in Nasopharyngeal Cancer Patients Treated with Intensity-Modulated Proton Therapy and Volumetric Modulated Arc Therapy at Different Time Points
Conclusions: Compared to VMAT, dose reduction attributed to IMPT could translate into better functional QoL and HN35 symptoms, but the effect is time dependent and exclusively observed during the RT phase. (Source: Cancers)
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Kuan-Cho Liao Yu-Jie Huang Wen-Ling Tsai Chien-Hung Lee Fu-Min Fang Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1221: Diagnosis of Metastatic Non-Small Cell Lung Cancer during Hospitalization: Missed Opportunity for Optimal Supportive Care?
Conclusion: Patients with new inpatient diagnoses of metastatic NSCLC have extremely poor outcomes. Current management strategies resulted in few patients starting systemic therapy, yet most of the patients did not receive palliative care or hospice involvement. These findings demonstrate that there is a high unmet need to optimally support and palliate these patients. (Source: Cancers)
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Shristi Upadhyay Banskota Jonathan Q. Trinh Elizabeth Lyden Conor Houlihan Samia Asif Omar Abughanimeh Benjamin A. Teply Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1201: Stage Shifting by Modifying the Determinants of Breast Cancer Stage at Diagnosis: A Simulation Study
Conclusion: Shifting the breast cancer stage at diagnosis of a population may be achieved through changes to lifestyle factors. This proof of principle study that evaluated multiple factors associated with the stage at diagnosis in a population can be expanded to other cancers as well, providing opportunities for cancer prevention programs to target specific factors and identify populations at higher risk. (Source: Cancers)
Source: Cancers - March 19, 2024 Category: Cancer & Oncology Authors: Gyanendra Pokharel Qinggang Wang Momtafin Khan Paula J. Robson Lorraine Shack Karen A. Kopciuk Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1203: Endobronchial Ultrasound Using Guide Sheath-Guided Transbronchial Lung Biopsy in Ground-Glass Opacity Pulmonary Lesions without Fluoroscopic Guidance
This study evaluates the utility of radial probe endobronchial ultrasound-guided transbronchial lung biopsy (RP-EBUS-TBLB) in diagnosing GGO pulmonary lesions. A total of 1651 RP-EBUS procedures were performed during the study period. This study analyzed 115 GGO lesions. The EBUS visualization yield was 80.1%. Of 115 lesions, 69 (60%) were successfully diagnosed. The average size of diagnosed lesions was significantly larger than that of undiagnosed lesions (21.9 ± 7.3 vs. 17.1 ± 6.6 mm, p < 0.001). Diagnostic yield varied by lesion size: 50.0% for lesions <20 mm, 65.1% f...
Source: Cancers - March 19, 2024 Category: Cancer & Oncology Authors: Jongsoo Park Changwoon Kim Jong Geol Jang Seok Soo Lee Kyung Soo Hong June Hong Ahn Tags: Article Source Type: research

Cancers, Vol. 16, Pages 1202: Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas
Qazi LGG tumors are characterized by a low infiltration of immune cells, requiring therapeutic interventions to boost the immune response. We conducted a study analyzing mRNA expression datasets from the UCSC Xena web platform. To screen for upregulated genes, we sought to compare normal brain tissue with LGG tumor samples. We also used cBioportal to determine the relationship between mRNA expression levels of 513 LGG patients and their overall survival (OS) outcomes. Three tumor-associated macrophage (TAM) markers, MSR1/CD204, CD86, and CD68, exhibited a 6-fold (p < 0.0001), 8.9-fold (p < 0.0001...
Source: Cancers - March 19, 2024 Category: Cancer & Oncology Authors: Vuong Trieu Anthony E. Maida Sanjive Qazi Tags: Article Source Type: research